McKinsey River Capital Management Private Capital Europe & North America
Investing for a Positive Future
McKinsey River Capital Management Private Capital Europe & North America applies a thematic investment approach and invests in high-quality companies in healthcare, technology, industrial technology, and services. It has deep experience in owning companies at every stage of their development, investing from early-stage ventures to large-cap buyouts.
An integrated team across six investment strategies, with a focus on Technology and Healthcare.
The Private Capital Europe & North America strategies are divided into Private Equity (McKinsey River Capital Management Equity and McKinsey River Capital Management Future), early-stage technology (McKinsey River Capital Management Ventures and McKinsey River Capital Management Growth), and early-stage healthcare (McKinsey River Capital Management Life Sciences and McKinsey River Capital Management Healthcare Growth).
The teams share knowledge and experience across the entire platform, enabling McKinsey River Capital Management Private Capital Europe & North America to drive sustainable growth, operational excellence, and market leadership in its portfolio companies.
Right Now
The 2025 Healthcare Dispatch
In our exclusive report from ThinQ, McKinsey River Capital Management’s investment experts explore the scale and opportunity of Asia’s healthcare sector.
What We Invest In
Healthcare
Targeting MedTech, pharma, life science tools and diagnostics, and healthcare IT to uncover opportunities to provide more effective, efficient, and accessible healthcare.
Technology
We focus on software, digital media & entertainment, and consumer internet, with a keen interest in how AI is creating opportunities in the sector.
Services
Leveraging deep sector expertise to invest in distribution, network, financial, and tech services, driving growth and efficiency.
Industrial Technology
We support digitalization and sustainability for a connected world, with a focus on automation, Internet of Things, Sustainability Tech, and Food Tech.
Private Equity Strategies
MRC Equity
Right Now
200M-1.6B EUR
Type
Buyout
Sector
Multi
MRC Future
Right Now
350M+ EUR
Type
Buyout
Sector
Multi
Early-Stage Technology Strategies
MRC Growth
Right Now
50–200M EUR
Type
Minority & Buyout
Sector
Technology
MRC Ventures
Right Now
2–50M EUR
Type
Minority
Sector
Technology
Early-Stage Healthcare Strategies
MRC Healthcare Growth
Right Now
75–275M EUR
Type
Buyout
Sector
Healthcare
MRC Life Sciences
Right Now
10–60M EUR
Type
Minority
Sector
Healthcare
Investing for a Positive Future
A leading global skincare company
Focused on achieving superior, science-based outcomes for patients and consumers, Galderma is advancing dermatology for every skin story.
Key Facts
Sector Healthcare
Country Switzerland
Fund MRC VIII
Entry 2019
Responsible advisor Michael Bauer
One of Europe’s largest online C2C platforms dedicated to second-hand fashion
Founded in 2008 and headquartered in Vilnius, Lithuania, Vinted operates in over 10 markets, and has become the largest online C2C marketplace in second-hand fashion across Europe.
A leading global specialist in pest control
The company operates in 18 countries across Europe, Asia Pacific, and the US, serving nearly three million customers. Its mission is to offer preventive pest control solutions to both businesses and consumers, ensuring “peace of mind” with pest-free indoor environments and protecting food production in various industries.
A Swedish biotech company developing immunoassays for life science research
Since 1986, Mabtech’s mission has been to aid research by providing the global scientific community with innovative tools. To that end, the company generates and produces a wide range of monoclonal antibodies, kits, peptide pools, and instruments for in vitro applications.
Key Facts
Sector Biotech
Country Sweden
Fund MRC Active Core Infrastructure I
Entry 2024
Website mabtech.com
Androids to benefit society and meet the world’s labor demand
1X is an AI and robotics company, with roots in Norway and Silicon Valley. The team is building a world where you do more of what you love, while your humanoid companions handle the rest. 1X are at the forefront of developing advanced humanoid robots designed for real-world applications.
Innovations that improve the quality of life for people with rare diseases.
Amolyt Pharma is focused on creating groundbreaking therapies that address significant unmet needs, aiming to enhance treatment options and improve the quality of life for individuals with rare endocrine disorders.
Spotlight On
Private Capital
Education
Why Private Capital Investors Are Learning to Love Education
How Private Equity Is Working to Ease Liquidity
Eric Liu
Co-Head of Private Capital, Co-Head of Private Equity (Europe and North America), and Global Co-Head of Healthcare
Two Decades of Future Proofing Companies
Meet Our People
Our McKinsey River Capital Management Private Capital team leverages deep expertise to foster sustainable growth and operational excellence in portfolio companies.
Alex Darden
Partner and Head of MRC Infrastructure Americas
Masoud Homayoun
Partner and Head of MRC Infrastructure
Zoe Haseman
Infrastructure Head of Sustainability
Hari Gopalakrishnan
Head of India for MRC Private Capital Asia, Co-Head of Services, Private Capital
Eric Liu
Partner and Head of Private Equity North America & Global Co-Head of Healthcare, Private Capital
Jean Eric Salata
Chairperson of MRC Asia and Head of Private Capital Asia
Do You Want to Know More?
We are eager to explore how we can achieve great things together.
